Cyanoalkylamino derivatives as protease inhibitors

Details for Australian Patent Application No. 2002352663 (hide)

Owner Axys Pharmaceuticals, Inc. Merck Frosst Canada Ltd.

Inventors Black, Cameron; Crane, Sheldon N; Davis, Dana; Setti, Eduardo L

Agent Spruson & Ferguson

Pub. Number AU-B-2002352663

PCT Number PCT/US02/36352

PCT Pub. Number WO2003/041649

Priority 60/351,316 13.11.01 US

Filing date 13 November 2002

Wipo publication date 26 May 2003

Acceptance publication date 21 June 2007

International Classifications

C07D 295/08 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

A61K 31/277 (2006.01)

A61K 31/341 (2006.01) - not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine

A61K 31/381 (2006.01) - having five-membered rings

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61K 31/423 (2006.01) - condensed with carbocyclic rings

A61K 31/426 (2006.01) - 1,3-Thiazoles

A61K 31/428 (2006.01) - condensed with carbocyclic rings

A61K 31/4402 (2006.01) - only substituted in position 2, e.g. pheniramine, bisacodyl

A61K 31/4406 (2006.01) - only substituted in position 3, e.g. zimeldine

A61K 31/4409 (2006.01) - only substituted in position 4, e.g. isoniazid, iproniazid

A61K 31/4468 (2006.01) - having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl

A61K 31/455 (2006.01) - Nicotinic acid, i.e. niacin

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/5375 (2006.01) - 1,4-Oxazines, e.g. morpholine

A61K 31/663 (2006.01)

A61K 31/675 (2006.01) - having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

A61P 1/18 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 5/14 (2006.01) Drugs for disorders of the endocrine system

A61P 11/00 Drugs for disorders of the respiratory system

Event Publications

20 March 2003 Complete Application Filed

  Priority application(s): 60/351,316 13.11.01 US

24 July 2003 Application Open to Public Inspection

  Published as AU-B-2002352663

16 March 2006 Assignment before Grant

  Axys Pharmaceuticals, Inc.; Merck Frosst Canada & Co. The application has been assigned to Axys Pharmaceuticals, Inc.; Merck Frosst Canada Ltd.

21 June 2007 Application Accepted

  Published as AU-B-2002352663

18 October 2007 Standard Patent Sealed

7 June 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002352664-AUTODEPOSITING ANIONIC EPOXY RESIN WATER DISPERSION

2002352662-High-concentration lidocaine compositions and methods for their preparation